This activity is part of the curriculum in the American College of Cardiology’s RIGHTSTEPS: Optimizing Medical Therapy for Chronic Heart Failure. The initiative seeks to ensure patients with chronic heart failure receive the right guideline-dictated medication. The program is committed to providing education that offers clinicians the right steps to treat the right patients with the right drugs at the right dose at the right time.
To see more information about RightSTEPS, including details about live meetings and after-education coaching, please click here.
All online activities for RightSTEPS are listed below, with links for those currently available.
Viewpoints in Heart Failure 1. Heart Failure Nation: Taking a Hard Look at Implications (Coming Soon) 2. The Impact of HFrEF vs HFpEF: How Do We Measure Up? (Coming Soon) 3. Falling Short on Simple Guideline Directed Care for Heart Failure (Coming Soon) 4. Sacubitril/Valsartan: A Game Changer in HF Treatment (Coming Soon) 5. Ivabradine: A Game Changer in HF Treatment (Coming Soon) 6. Interrupting the Revolving Door of HF Hospitalization and Readmission (Coming Soon) 7. Navigating the MIPS Maze (Coming Soon)
Online Reinforcing Activities 1. How to Reduce Performance Variation in Heart Failure Management—Conference Capture (Coming Soon) 2. Concerns and Controversies Over New Treatments in Heart Failure (Coming Soon)
0.50 / AMA PRA Category 1 CreditTM 0.50 / CNE Contact Hour
Provided by the American College of Cardiology Foundation in collaboration with Haymarket Medical Education
Supported by an educational grant from Novartis Pharmaceuticals Corporation
In 2015, the US Food and Drug Administration (FDA) approved sacubitril/valsartan, making it one of the first pharmacologic therapies to emerge for chronic heart failure (HF) management in more than a decade. Sacubitril/valsartan approval was based primarily on the results of the PARADIGM-HF study, which randomized 8442 patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) to either sacubitril/valsartan or enalapril. After a median follow-up of 27 months, sacubitril/valsartan treatment was associated with a 20% reduction in the combined primary end point of death or HF hospitalization and a 16% reduction in all-cause death compared with enalapril. Education is needed on how sacubitril/valsartan can be incorporated into treatment planning for chronic HF.
This module is intended for cardiologists, internists, primary care physicians, nurses, nurse practitioners (NPs), physician assistants (PAs), and other clinicians who manage patients with chronic heart failure.
At the conclusion of this activity, participants should be better able to:
Evaluate the safety, efficacy, and mechanism of action (MOA) of sacubitril/valsartan
Utilize sacubitril/valsartan in patients as appropriate
Accredited Provider Disclosure of Conflicts of Interest Statement and Disclosure Policy
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC), the American College of Cardiology Foundation (ACCF) must ensure balance, independence, objectivity, and scientific rigor in all of its directly provided or jointly provided/co-provided educational activities. Planners, presenters, and other contributors in a position to control the content are required to disclose to the audience all relevant financial relationships he/she and/or his/her spouse or domestic partner may have, occurring within the past 12 months, with any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by, or used on, patients. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the contributor should disclose that the product is not labeled for the use under discussion or that the product is still investigational.
ACCF is committed to providing its learners with high-quality activities and materials that promote improvements and quality in healthcare and not a specific proprietary business or commercial interest. The intent of this disclosure is not to prevent participation in certified educational activities by persons with a financial or other relationship, but rather to provide learners with information on which they can make their own determination whether financial interests or relationships may influence the certified activity.
ACCF assesses conflict of interest (COI) with its faculty, planners, managers, staff, and other individuals who are in a position to control the content of certified CME/CNE activities. All relevant potential conflicts of interest that are identified are thoroughly vetted by course directors, ACCF education staff, and members of the Accreditation Compliance Workgroup through a process that includes appropriate peer review for fair balance, scientific objectivity and validity, and patient care and safety recommendations.
Margaret Bowers, DNP, RN, FNP-BC, CHFN, AACC, FAANP Associate Professor Faculty Coordinator, Adult Nurse Practitioner Programs Lead Faculty, Cardiovascular Specialty Duke University School of Nursing Durham, NC
Margaret Bowers, DNP, RN, FNP-BC, CHFN, AACC, FAANP, has received speaker’s bureau fees from Amgen.
Akshay Desai, MD, MPH, FACC Director, Heart Failure Disease Management Cardiovascular Division Brigham and Women’s Hospital Associate Professor of Medicine Harvard Medical School Boston, MA
Akshay Desai, MD, MPH, FACC, reports receiving research grants from Novartis and consulting fees from Novartis, St. Jude Medical, Relypsa, Sanofi, Merck, Janssen, AstraZeneca, and Cheetah Medical.
Alan Wasserman, MD, MACP, FACC Chairman, Department of Medicine Eugene Meyer Professor of Medicine George Washington School of Medicine & Health Sciences George Washington University Medical Center Washington, DC
Alan Wasserman, MD, MACP, FACC, has no relevant financial relationships to disclose.
Cathleen Biga, RN, MSN President and CEO Cardiovascular Management of Illinois Woodridge, IL
Cathleen Biga, RN, MSN, has no relevant financial relationships to disclose.
Kimberly V. Cheramie, MSN, RN-BC Nurse Planner American College of Cardiology Washington, DC
Kimberly V. Cheramie, MSN, RN-BC, has no relevant financial relationships to disclose.
Lee Goldberg, MD, MPH Medical Director University of Pennsylvania Heart Failure and Transplantation Program Associate Professor of Medicine Hospital of the University of Pennsylvania Philadelphia, PA
Lee Goldberg, MD, MPH, has received consultant fees from Medtronic and St. Jude Medical and has received research grants from Respircardia.
Biykem Bozkurt, MD, PhD Professor of Medicine Director, Winters Center for Heart Failure Associate Director, CVRI Baylor College of Medicine Medical Care Line Executive Debakey VAMC Houston, TX
Biykem Bozkurt, MD, PhD, has received clinical trial fees from Novartis Pharmaceuticals Corporation.
Accredited Provider Disclosures
ACCF staff involved in this activity have no relevant financial relationships to disclose.
Haymarket Medical Education staff involved in this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The ACCF designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME.
CNE Contact Hour(s)
The American College of Cardiology Foundation is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
The ACCF designates this educational activity for a maximum of 0.50 continuing nursing education contact hour. Requirements for successful completion are viewing of module in its entirety and completing the evaluation tool.
While offering credits noted above, the module is not intended to provide extensive training or certification in the field.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The American College of Cardiology Foundation (ACCF) is not responsible for statements made by any contributor. Statements or opinions expressed in this program reflect the views of the contributors and do not reflect the official policy of the ACCF.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have an American College of Cardiology (ACC) account, you can choose to have your credit information sent to your ACC Transcript upon completion of the course. You will be prompted to log in to your ACC account, which will automatically trigger your credit submission. If you do not have an ACC account, you will have the opportunity to create one.
ACCF Learner Bill of Rights
The ACCF recognizes that you are a lifelong learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge or skill and to attain or enhance a desired competency. As a participant in an ACCF activity, you have the right to expect that your continuing medical education experience with ACCF includes the following.
Promotes improvements or quality in healthcare
Is current, valid, reliable, accurate, and evidence-based
Addresses the stated objectives or purpose
Is driven and based on an independent survey and analysis of learner needs, not commercial interests
Has been reviewed for bias and scientific rigor
Offers balanced presentations that are free of commercial bias
Is vetted through a process that resolves any conflicts of interest of planners and faculty
Is evaluated for its effectiveness in meeting the identified educational need
A learning environment that:
Is based on adult learning principles that support the use of various modalities
Supports learners’ abilities to meet their individual needs
Respects and attends to any special needs of the learners
Respects the diversity of groups of learners
Is free of promotional, commercial, and/or sales activities
Relevant financial relationships that planners, teachers, and authors have with commercial interests related to the content of the activity
Commercial support (funding or in-kind resources) of this activity